Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Explore the interplay between diabetes and mental health conditions, the consequences and implications for clinical practice, and the role of endocrinologists in recognizing and managing psychological difficulties.
While there is some debate whether upfront combination therapy versus the traditional stepwise approach is more beneficial for LDL-C reduction, the suitability of either strategy is patient-dependent. Here is what to consider.
The novel oral GLP-1 receptor agonist orforglipron shows noninferior and potentially superior glycemic control versus oral semaglutide in type 2 diabetes, but with more gastrointestinal adverse events.
Metabolic and renal dysfunctions can influence the disease trajectory, treatment response, and prognosis of cardiomyopathies. A holistic and multidisciplinary approach is key to identifying the appropriate therapies.
Biotics have the potential to improve metabolic syndrome by reducing weight gain, insulin resistance, dyslipidemia, inflammation, and improving glycemic control and gut barrier function.
The global burden of ALD is growing and compounded by frequent late-stage diagnosis and undertreatment. Get the latest insights and advances in alcohol-associated liver disease, from patient risk and identification to treatment and management, plus the arrival of MetALD and what it means for patient care.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
A 6-year-old girl with early onset, severe obesity fulfilling the criteria for ROHHAD syndrome was found to have variants in PLXNA3 and PCSK1, genes involved in the leptin‒melanocortin pathway and associated with monogenic obesity.
Coronary aneurysms may present with nonspecific symptoms, delaying appropriate management. A suspected cardiac tumor in this patient was revealed to be a giant right coronary artery aneurysm, which was successfully managed with aneurysmectomy and CABG.
Laparoscopic sleeve gastrectomy was performed on a heart-transplant recipient to manage post-transplant weight gain and mitigate rejection risks. Improvements in cardiac function, metabolic parameters, and liver and kidney function suggest the procedure might benefit these high-risk patients
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
Intermittent fasting (IF) aids the management of obesity and impaired glucose homeostasis, although the comparative efficacy of different modes of IF on glycemic control remains unclear. The current review therefore aimed to investigate the …
Atypical diabetes subtypes and presentations are disproportionately prevalent in populations of African and Asian ancestry. This review discusses the epidemiology, clinical presentation, aetiopathogenesis and management of four atypical diabetes …
The gut microbiota (GM) is a pivotal regulator of host metabolism and a contributor to the pathophysiology of obesity, type 2 diabetes (T2D), and metabolic syndrome (MS). Disruptions in GM composition and function are collectively termed …
Metabolic and Bariatric Surgery (MBS) is an established treatment for obesity and its associated metabolic conditions. As obesity prevalence has risen globally over the past two decades, so too has MBS utilization, spurring interest in same-day …
Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills with real cases, vodcasts, and interactive infographics.
Treating children with hormone disorders is complex and requires tailored management. To help you provide the most effective care, we deliver news, cases and expert reviews covering adrenal, thyroid, pituitary, growth, and puberty disorders, obesity, and diabetes.
Obesity has emerged as a significant national and global health challenge. Data indicate the global prevalence of overweight and obesity has rose markedly from 1990 to 2021, with a 155.1% increase in men and a 104.9% increase in women. By 2050, it …
Metabolic bariatric surgery (MBS) is the most effective treatment option for achieving sustained weight loss in patients with obesity, while also improving obesity associated medical problems [ 1 , 2 ]. Among the various surgical options, Roux-en-Y …
Obesity is a global health issue that leads to an increase in morbidity but also in all-cause mortality. Today, metabolic and bariatric surgery (MBS) is commonly provided as an effective procedure for weight loss that also has beneficial secondary …
In this position statement, the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) highlights the evaluation of ring-augmented procedures in Metabolic Bariatric Surgery (MBS). A GRADE-based systematic review and …
The novel oral GLP-1 receptor agonist orforglipron shows noninferior and potentially superior glycemic control versus oral semaglutide in type 2 diabetes, but with more gastrointestinal adverse events.